With biotech technology progressing at an ever increasing rate, the question has changed – instead of merely focusing on curing various illnesses and conditions, prevention has taken the spotlight.
In fact, according to Trust for America’s Health (TFAH) and the Robert Wood Johnson Foundation (RWJF), 71% of Americans are in favor of increased investment when it comes to disease prevention. More accessible healthcare, early detection and genetic screening have become popular topics of discussion and have the public wondering what could be next…
Early detection of cancer, liver disease and alzheimers could potentially change medical industry forever
Early detection of conditions, diseases and varying illnesses can be challenging, but numbers show that it has an incredible impact on health and survivability. In terms of cancer, early detection has been the key to survival – 90% of people survive bowel cancer if it is caught at the earliest stage, according to Professor Jane Warle and that’s merely one area.
Despite statistics like that, however, the rate of people who get regularly tested is low and that’s in a large part because of the lack of accessible and non-invasive options. Some options include painful or uncomfortable procedures or even exploratory surgery and that’s enough to put a lot of people off. There is, however, one company that has evolved past the need for discomfort – Breathtec Biomedical Inc. (OTCQB: BTHCF – website: here) could become the future of disease detection, specializing in the early detection of life-threatening illnesses and perhaps best of all, in a non-invasive procedure.
How Does This Non-Invasive Disease Detection Device Look?
Photo: Breathtec Breathing Device Presented on CBC
Photo: Breathtec Breathing Device
Recently, the company announced that it plans to begin clinical trials of the core technology for its product. The clinical trials, which will be held at the renowned Innovation Boulevard in Surrey, British Columbia, will be an intensive research review into NA-NOSE, which has been in-licensed by Breathtec and is an advanced stage, nanotechnology-based breath analysis device from the Technion – Israel Institute of Technology.
Breathtec Biomedical, Inc. has entered into a license agreement with the Technion Research and Development Foundation Ltd., an Israeli private company and wholly-owned subsidiary of the Technion – Israel Institute of Technology (“Technion”), with respect to NA-NOSE, an advanced stage breath analysis technology
Dr. Haick is the recipient of the prestigious Marie Curie Excellence Award, ERC Award, and the FP-7 and Horizon 2020 consortium Awards. He is also the recipient of more than 56 international honors and prizes for his achievements. Prof. Haick has published over 170 articles and serves on the editorial board of several peer-reviewed journals, and is a senior scientific advisory member of several national and international companies and institutes.
Photo: Dr. Haick and Bill Gates
Breathtec Device is booming in the news:
Breathtec has been featured on CBC News in Canada and called – “Battling Disease with Breath”
Recently Global News (globalnews.ca) called Breathtec – “A ‘breathalyser’ for diseases”. Check company’s latest video update and stock quote BTHCF
How Big is The Medical Device Market?
How Breathtec Technology Works?
Michael Bousamra, M.D. and a team of researchers from the University of Louisville developed a silicone microprocessor and mass spectrometer that has shown 95% accuracy in detecting specific compounds associated with lung cancer – in practice, it was 95% accurate when it came to predicting the malignancy of tumors as well. In effect, BreathTec currently owns the University of Florida patent U.S 8,237,118, “Partial Ovoidal FAIMS Electrode”, a mass spectrometry technique that exploits the differences in ion mobility at very high electric fields to separate ions in the millisecond timescale after liquid chromatography separation and prior to introduction to a mass spectrometer.
What this technology can accomplish is the miniaturization of breath testing devices and the development of non-invasive clinical screening which will save lives.
It’s accessible too and can be used in a clinic, a hospital or anywhere else you’d need it, meaning it can be made use of by just about anyone.
What Could This Mean For Consumers and Investors?
The economic impact a technique like this could be measured in the billions – because anything in your body that reaches your blood can be detected in your breathe, it’s only a matter of time before breath tests become the norm in hospitals, clinics and doctor’s offices nation as well as world wide. The ability to early detect conditions like cancer, Alzeimers and Parkinsons, heart disease and diabetes and more will not only improve the overall health of human kind, but take a massive burden of the already overloaded medical industry. Breath analysis is quickly becoming a favored method by health care professionals for it’s rapid results, relatively low cost and it’s safety.
The ultimate goal is to create something affordable and portable in both desktop and handheld sizes so it can be used anywhere, by anyone, with little effort.
Could This Innovative Technology Be The Next Big Thing?
It’s no surprise that medical technology tend to be the hottest niche in 2016, because it’s one of the largest industries on the planet in almost every country on Earth. It’s not just favored in terms of ROI, but because it’s an industry that makes a real difference, promoting the health and well-being of us all, saving and bettering lives. While medical technology giants like Johnson & Johnson eat up a massive market share with $27.5 billion revenue in 2014, others stars are rising and there is a massive push towards diagnostic and prevention care that’s begging for a contender. Diagnostic imaging alone had an annual revenue of $35.6 billion and is expected to increase to $40.9 billion in 2020, leaving room for exponential growth as one of the fastest growing segments of technology.
Significant Growth Have Historically Been Found in the Biotech Market
According to CNN Money, 4 out of 5 of the Best Performing IPOs in 2015 have been pharmaceutical and biotech companies including companies such as Spark Therapeutics Inc and Aduro BioTech Inc.
Perfect Momentum for BreathTec?
The momentum at BreathTec (OTCQB: BTHCF) has been…well, breathtaking. In the first half of 2016 alone, the company began publicly trading on the Canadian Securities Exchange and the OTC Markets, and added a number of industry leaders to its team. In June, Breathtec appointed industry veteran Guy LaTorre as CEO. LaTorre brings with him over 25 years of experience in the healthcare industry, including being a co-founder of Novamin Technology Inc. Novamin Technology Inc. was successfully sold to GlaxoSmithKline (GSK) in 2010 for USD $135 million.
Breathtec Biomedical (OTCQB: BTHCF) is uniquely positioned to propel innovative research in the area of diagnostics with the ultimate goal of furthering early detection technology. Unlike competitors, who use blood and tissue tests, they’re taking advantage of exciting new breath-based analysis and are truly delivering something new and innovative, something bound to change the medical world forever.
More information about the BreathTec: breathtecbiomedical.com
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This is a Native Advertisement, meaning it is an informational paid marketing piece. Finance-monthly.com makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Please review all investment decisions with a licensed investment advisor.
This Advertorial contains forward-looking statements that involve risks and uncertainties. This Advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured Company. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s)” “anticipate(s)”, “plan(s)” “expect(s)” “project(s)” “will” “make” “told” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cau se actual events or actual results of the Company to differ materially from these indicated by such forward-looking statements. Certain statements contained herein constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the Company, or contained in this advertorial are not guarantees of future performance, and that the Issuer’s actual results may differ materially from those set forth in the forward-looking statements. Difference in results can be caused by various factors including, but not limited to, the Company’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this advertorial contains “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this advertorial may be identified through the use of words such as “expects,” “will,” “anticipates,” “estimates,” “believes,” “may,” or by statements indicating certain actions “may,” “could,” or “might” occur. More information on the Company may be found at http://www.sec.gov; readers can review all public filings by the Company at the SEC’s EDGAR page. Finance-Monthly.com is not a certified financial analyst or licensed in the securities industry in any manner. The information in this Advertorial is subjective opinion and may not be complete, accurate or current and was paid for, so this could create a conflict of interest.